Influenza News
| Mar 9, 2010 – SOURCE: Vaccine | |||
 |
|
Determinants of influenza immunization uptake in Canadian youths | |
| OBJECTIVE: To describe rate and determinants of influenza vaccination among Canadian youths. METHODS: We conducted an analysis of cross-sectional data from the Canadian Community Health Survey (CCHS) cycle 3.1 collected by Statistics Canada in 2005. This | |||
| Mar 9, 2010 – SOURCE: Pediatric Blood & Cancer | |||
|
|
Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy | |
| PURPOSE: The aim of this study was to assess the immune response of children with acute lymphoblastic leukemia (ALL) to influenza vaccine and to compare it with healthy controls. PROCEDURE: Thirty-two children aged 1-18 years with ALL on maintenance thera | |||
| Mar 8, 2010 – SOURCE: Liver Transplantation | |||
|
|
Severe novel H1N1 influenza A infection in the immediate postoperative period of a liver transplant patient | |
| In 2009, the World Health Organization recognized the novel H1N1 influenza A virus as a pandemic infection. Since April 2009, thousands of cases of novel H1N1 influenza A infection have been reported worldwide, and they have resulted in thousands of death | |||
| Mar 8, 2010 – SOURCE: American Journal of Respiratory and Critical Care Medicine | |||
|
|
Pandemic 2009 Influenza A(H1N1) in Argentina: A Study of 337 Patients on Mechanical Ventilation | |
| RATIONALE: The rapid spread of the 2009 Influenza A(H1N1) around the world underscores the need for a better knowledge of epidemiology, clinical features, outcomes, and mortality predictors, especially in the most severe presentations. OBJECTIVES: To desc | |||
| Mar 8, 2010 – SOURCE: Clinical Rheumatology | |||
|
|
Influenza H1N1 infection in a patient with psoriatic arthritis in treatment with Adalimumab: a case report | |
| In March 2009 was the beginning of an epidemic flue caused by avian influenza A virus H1N1. The disease varies from mild to serious and fatal cases. There are many hypotheses explaining why this virus infection would be fatal. One of these is the impaired | |||
| Mar 8, 2010 – SOURCE: Cancer Chemotherapy and Pharmacology | |||
|
|
Serological immune responses to influenza vaccine in patients with colorectal cancer | |
| BACKGROUND: The immune responses to influenza vaccination in patients with colorectal cancer on surveillance or active chemotherapy have not been previously reported. We conducted a prospective influenza vaccination study to determine the serological immu | |||
| Mar 5, 2010 – SOURCE: Annals of Tropical Paediatrics: International Child Health | |||
|
|
Swine-origin influenza A (H1N1) in Indian children | |
| BACKGROUND: Swine-origin influenza A H1N1 (S-OIV) has not been systematically studied in Indian children. OBJECTIVES: To study the clinical characteristics, morbidity and mortality pattern in children with S-OIV infection. METHODS: This prospective study | |||
| Mar 4, 2010 – SOURCE: Clinical Infectious Diseases | |||
|
|
Effects of Early Oseltamivir Therapy on Viral Shedding in 2009 Pandemic Influenza A (H1N1) Virus Infection | |
| Background. Pandemic influenza (H1N1) 2009 is susceptible to oseltamivir. There are few reports on its clinical and virologic response to oseltamivir. Methods. During the pandemic containment response in Singapore, all patients with positive polymerase ch | |||
| Mar 4, 2010 – SOURCE: American Journal of Medicine | |||
|
|
Severe H1N1-Associated Acute Respiratory Distress Syndrome: A Case Series | |
| BACKGROUND: Acute respiratory distress syndrome resulting from novel influenza A virus (H1N1) infection remains uncommon. METHODS: We describe the clinical profiles of adult patients with acute respiratory distress syndrome due to microbiologically confir | |||
| Mar 3, 2010 – SOURCE: International Journal of Antimicrobial Agents | |||
|
|
Safety and pharmacokinetics of oseltamivir at standard and high dosages | |
| Although clinical evidence is currently lacking, opinion in the literature on avian influenza A/H5N1 suggests that increased doses of the oral neuraminidase inhibitor oseltamivir may offer clinical benefits against highly pathogenic influenza where high l | |||
